Surrozen, Inc. cash flow statement
In fiscal 2025, Surrozen, Inc.'s operations generated −$30.2m of cash; it spent $128,000 on capital projects, leaving free cash flow of −$30.4m.
Cash flow statement
| Fiscal year | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|
| Cash from operations | −49 | −44 | −40 | −18 | −30 | −35 |
| Depreciation and amortisation | 2 | 2 | 2 | 1 | 1 | 0 |
| Stock-based pay | 2 | 5 | 4 | 4 | 4 | 7 |
| Capital spending | 1 | 1 | 0 | 0 | 0 | 0 |
| Free cash flow | −50 | −45 | −41 | −18 | −30 | −35 |
| Free cash flow after stock pay | −52 | −49 | −45 | −22 | −34 | −42 |
| Share buybacks | 0 | 3 | 0 | — | — | — |
| Shares issued | 124 | 0 | 0 | 16 | 75 | 4 |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | −7 | 3 | −9 | −6 | −9 | −6 | −12 | −7 |
| Depreciation and amortisation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based pay | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 |
| Capital spending | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | −7 | 3 | −9 | −6 | −9 | −6 | −13 | −7 |
| Free cash flow after stock pay | −8 | 3 | −10 | −7 | −10 | −7 | −15 | −10 |
| Shares issued | −0 | 0 | 76 | −5 | 0 | 4 | 0 | 0 |
Compare with peers
- Mindwalk Holdings Corp. cash flow
- Relay Therapeutics, Inc. cash flow
- Lineage Cell Therapeutics, Inc. cash flow
- Caribou Biosciences, Inc. cash flow
- Opus Genetics, Inc. cash flow
Head to head: HYFT vs SRZNRLAY vs SRZNLCTX vs SRZN
More: Biotechnology stocks compared, Health Care sector, rankings of US companies